Associated Papers
Expanding the clinical tumor phenotype of the EPAS1-asssociated tumor syndrome.
Cole Y et al.
The Journal of Clinical Endocrinology and Metabolism, 2026
Assessment of HIF2α mutational pathogenicity using microscale thermophoresis.
Ferens FG et al.
Biology Methods & Protocols, 2026
Deficiency in PHD2-mediated hydroxylation of HIF2α underlies Pacak-Zhuang syndrome.
Ferens FG et al.
Communications Biology, 2024
The Participation of the Intrinsically Disordered Regions of the bHLH-PAS Transcription Factors in Disease Development.
Kolonko-Adamska M et al.
International Journal of Molecular Sciences, 2021
Exosomal double-stranded DNA as a biomarker for the diagnosis and preoperative assessment of pheochromocytoma and paraganglioma.
Wang L et al.
Molecular Cancer, 2018
HIF-2α-pVHL complex reveals broad genotype-phenotype correlations in HIF-2α-driven disease.
Tarade D et al.
Nature Communications, 2018
ARHI is a novel epigenetic silenced tumor suppressor in sporadic pheochromocytoma.
Wang D et al.
Oncotarget, 2017
29156798 (PubMed )
Supplement: oncotarget-08-86325-s002.xls › Sheet1
Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis.
Comino-Méndez I et al.
Human Molecular Genetics, 2013
Select a paper to view details